Trials / Recruiting
RecruitingNCT06617416
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 560 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab (AK104) | AK104 ivgtt Q3W |
| DRUG | Sugemalimab | 1200mg Q3W |
Timeline
- Start date
- 2024-11-12
- Primary completion
- 2026-10-28
- Completion
- 2028-12-30
- First posted
- 2024-09-27
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06617416. Inclusion in this directory is not an endorsement.